,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'enhertu']
 was quoted in a article discussing the #tdxd (enhertu) drug. new data presented at #asco22 are from #breastcancers that have low levels of her2, meaning that a wider range of pts might benefit from the drug. 
Patient-centered care, clinical trials & translational research on breast cancer @DanaFarber and @HarvardMed. Appts: 877-442-3324, Clinical trials: 877-338-7425